Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of TT-173 Applied in the Donor Site of Patients Undergoing Skin Graft

NCT02012569 is registered in ClinicalTrials.gov with Thrombotargets Europe S.L as lead sponsor.

NCT NCT02012569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02012569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of TT-173 Applied in the Donor Site of Patients Undergoing Skin Graft
Lead sponsor
Thrombotargets Europe S.L
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2013
Completion date
July 31, 2015
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burns, traumatic lesions